I think this QR will achieve 60 EPS.

We should not be worried if there are other players entering medical industry. Because they might not be able to secure enough volumes/orders to achieve economy of scale in order to sustain the profitability. They might suffer losses years after years, and in the end forced to sell the glove manufacturing lines to the big 4 glove counter.

We should not be worried if there are other players entering medical industry. Because they might not be able to secure enough volumes/orders to achieve economy of scale in order to sustain the profitability. They might suffer losses years after years, and in the end forced to sell the glove manufacturing lines to the big 4 glove counter.

According to Topglove management, the Dividend Yield for 2021 will be more than 6% at RM7. Currently the share price is aroudn RM6, which means the Dividend Yield will be around 8%, it is higher than the yield in most of the bonds, and nearly quadraple of what FD is providing you.

hi Mr tan, my stock pick for 2021 is :
1. topglove - 20%
2. kossan - 20%
3. supermax- 20%
4. homeriz - 20%
5. serbadk -20%

Let's look at the facts, Karim had been acquiring shares since early this year, and he further subscribed for more share through Private Placement out of his own pocket.

Fundamentally, it has a very healthy operating cash flow and high earning visibility with strong order book.

Serba has a robust growth prospect, the owner is willing to subscribe the private placement out of his own pocket.

Last time when Dayang announced private placement, the share price took a plunge too, but after awhile it rebounded and rise all the way to RM3 when fantastic quarterly earning report is published!

Hi Mr Tan, please help to add me into the competition.

My pick for 2020 is as following:
1. Lctitan (15%)
2. Genting (15%)
3. Vstecs (15%)
4. FPI (15%)
5. Favco (15%)
6. Pie (15%)
7. APM(10%)